Literature DB >> 34126621

Serum Copper Level and Polycystic Ovarian Syndrome: A Meta-Analysis.

Qingtao Jiang1, Feng Zhang2, Lei Han2, Baoli Zhu2, Xin Liu2.   

Abstract

INTRODUCTION: The association of serum copper with polycystic ovarian syndrome (PCOS) has been studied for years, but no definite conclusion is drawn. Therefore, we conducted a meta-analysis to investigate serum copper concentrations in PCOS subjects compared with healthy controls.
METHODS: Electronic search was performed in PubMed, Google Scholar, and Scopus up to June 30, 2020, without any restriction. Standardized mean differences (SMDs) with corresponding 95% CIs in serum copper levels were employed with random-effects model. I2 was applied to evaluate heterogeneity among studies.
RESULTS: Nine studies, measuring plasma copper levels in 1,168 PCOS patients and 1,106 controls, were included. Pooled effect size suggested serum copper level was significantly higher in women with PCOS (SMD = 0.51 μg/mL, 95% CI = [0.30, 0.72], p < 0.0001). The overall heterogeneity was not connected with subgroups of the country, but derived from the opposite result of 1 study.
CONCLUSION: Our research generally indicated circulating copper level in PCOS sufferers was significantly higher than normal controls. Large-scale studies are still needed to elucidate the clear relation between copper status and etiology of PCOS.
© 2021 S. Karger AG, Basel.

Entities:  

Keywords:  Copper; Meta-analysis; Polycystic ovarian syndrome

Year:  2021        PMID: 34126621     DOI: 10.1159/000516518

Source DB:  PubMed          Journal:  Gynecol Obstet Invest        ISSN: 0378-7346            Impact factor:   2.031


  1 in total

1.  The Activity of Superoxide Dismutase, Its Relationship with the Concentration of Zinc and Copper and the Prevalence of rs2070424 Superoxide Dismutase Gene in Women with Polycystic Ovary Syndrome-Preliminary Study.

Authors:  Anna Bizoń; Agata Tchórz; Paweł Madej; Marcin Leśniewski; Mariusz Wójtowicz; Agnieszka Piwowar; Grzegorz Franik
Journal:  J Clin Med       Date:  2022-05-01       Impact factor: 4.964

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.